Wird geladen...
Combination of ruthenium(II)-arene complex [Ru(η(6)-p-cymene)Cl(2)(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being investigated as alternatives to other well-established metal-based chemotherapeutics. The organometallic compound [Ru(η(6)-p-cymene)Cl(2)(pta)], where pta = 1,3,5-triaza-7-phosphaadamantane (RAPTA-C) exhibits broad ac...
Gespeichert in:
| Veröffentlicht in: | Sci Rep |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Nature Publishing Group
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5320450/ https://ncbi.nlm.nih.gov/pubmed/28223694 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep43005 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|